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A B S T R A C T
The tumor microenvironment (TME) and metabolic reprogramming have been implicated in cancer development
and progression. However, the link between TME, metabolism, and cancer progression in lung cancer is unclear.
In the present study, we identified IMPAD1 from the conditioned medium of highly invasive CL1-5. High ex-
pression of IMPAD1 was associated with a poorer clinical phenotype in lung cancer patients, with reduced
survival and increased lymph node metastasis. Knockdown of IMPAD1 significantly inhibited migration/inva-
sion abilities and metastasis in vitro and in vivo. Upregulation of IMPAD1 and subsequent accumulation of AMP in
cells increased the pAMPK, leading to Notch1 and HEY1 upregulation. As AMP is an ADORA1 agonist, treatment
with ADORA1 inhibitor reduced the expression of pAMPK and HEY1 expression in IMPAD1-overexpressing cells.
IMPAD1 caused mitochondria dysfunction by inhibiting mitochondrial Complex I activity, which reduced mi-
tochondrial ROS levels and activated the AMPK-HEY1 pathway. Collectively this study supports the multipotent
role of IMPAD1 in promotion of lung cancer metastasis by simultaneously increasing AMP levels, inhibition of
Complex I activity to decrease ROS levels, thereby activating AMPK-Notch1-HEY1 signaling, and providing an
alternative metabolic pathway in energy stress conditions.
1. Introduction
Lung cancer is one of the most common malignancies in Taiwan and
remains the leading cause of cancer-related death globally, with more
than 1.3 million people dying of the disease annually [1]. Non–small-
cell lung carcinoma (NSCLC) cases account for approximately 80% of
all lung cancer cases [2,3]. Approximately 70% of all newly diagnosed
NSCLC patients exhibit locally advanced or metastatic disease and re-
quire systemic treatment. NSCLC patients often have a poor prognosis,
and the 5-year survival rate of patients at all stages combined is only
15% [3–5], concomitant with its high rate of metastasis [6].
The tumor microenvironment (TME) - including stromal-derived
enzymes, secretory proteins, and cytokines - drives the malignant
phenotype of cancer cells [7]. In recent years, focus has shifted in
particular to the secretome and the critical role that this plays in the
malignant phenotype of lung cancer cells [8,9]. The secretome refers to
the library of proteins that are released from cells, tissue, or organism
through different mechanisms, including classical secretion, non-clas-
sical secretion, membrane protein shedding, and exosomal secretion
[10–12]. Tumor progression to metastasis involves specific molecular
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interactions between cancer cells and the surrounding extracellular
matrix; however, how cancer cells regulate these molecular interactions
is not clearly defined [7]. Metabolic reprogramming - vital to cancer
cell survival under energy stress conditions, including anchorage-in-
dependent growth and solid tumor formation [13] – may additionally
play a role in such cancer cell and extracellular matrix interactions.
Aside from their role in energy production, mitochondria produce cel-
lular reactive oxygen species (ROS) that play a role in cellular signaling
[14,15], with modification of cellular physiology and molecular sig-
naling by regulation of ROS concentration [16]. In this regard, cancer
cells may increase antioxidant levels to maintain homeostasis, while
chemotherapeutic drugs may kill cancer cells by increasing ROS levels.
Alternatively, targeting antioxidants may cause cancer cells to produce
ROS [17,18].
In order to answer some of these critical questions regarding tumor
microenvironment and metabolic reprogramming, we therefore speci-
fically focused on proteins relevant to cancer metabolism in the se-
creted proteins differentially expressed in lung cancer cells. This high-
lighted the potential role of inositol monophosphatase domain-
containing 1 (IMPAD1), the enzyme responsible for the hydrolysis of
phosphoadenosine phosphate (PAP) to adenosine monophosphate
(AMP), in lung tumor metastasis and migration. Other than its location
in Golgi [32], IMPAD1 is also identified from the exosome isolated from
the conditioned medium of CL1-5 lung cancer cells [8]. In this study we
explored both a novel metastasis promoting pathway involving
IMPAD1-AMPK-Notch1-Hey1, and a potential alternative metabolic
pathway to AMPK activation in NSCLC.
2. Materials and methods
2.1. Cell lines and conditioned medium
CL1-0, CL1-5, H441, and H460 lung cancer cell lines were cultured
in RPMI-1640 medium containing 10% FBS and 1% PSG. The
H1299 cell line was maintained in DMEM containing 10% FBS and 1%
PSG. For preparing CM, CL1-0 and CL1-5 lung cancer cell lines were
plated at 3 × 105 cells/well in a 6-well plate and were incubated for
24 h at 37 °C. After 24 h, the cells were washed with serum-free
medium (SFM) and incubated in SFM for 24 h at 37 °C. On the next day,
CM was collected into Ultra-15 tubes (molecular weight cut-off: 3 kDa;
Millipore, Billerica, MA, USA). The BCA assay (Pierce™ BCA Protein
Assay Kit; Thermo Fisher, IL, USA) was used to determine the protein
concentration.
2.2. Immunoblotting
Proteins were extracted using RIPA buffer, and the protein con-
centration was measured using the BCA protein assay kit (Pierce™ BCA
Protein Assay Kit; Thermo Fisher, IL, USA). Proteins from cell lines or
CM were loaded onto SDE-PAGE gel (10%). After being transferred to a
PVDF membrane, blocking with 5% BSA in TBST was conducted. The
antibodies and condition are listed in Supplemental Table S4.
2.3. Lentiviral infection
Lentiviral particles of IMPAD1 were purchased from GeneCopoeia
(#W1522, MD, USA). Viral supernatants of IMPAD1, HEY1, and Notch1
shRNA were purchased from the National RNAi Core Facility Platform
(Taipei, Taiwan; target sequences are provided in Table S4). Viral su-
pernatants were used to infect lung cancer cells in complete medium
containing 8 μg/mL polybrene. After 72 h, the cells were selected using
2 μg/mL puromycin.
2.4. Online data analysis
We used a publicly available lung cancer microarray to construct
the overall survival curve using the Kaplan–Meier method; the curve
was stratified according to the expression of IMPAD1 and ADORA1
(http://kmplot.com/analysis/index.php?p=service& cancer=lung)
[19]. PrognoScan is a microarray database that presents the hazard
ratio by statistical expression of target genes and survival in patient
samples (http://dna00.bio.kyutech.ac.jp/PrognoScan/). The IHC
staining results of normal tissues and cancer tissues were obtained from
the HPA (https://www.proteinatlas.org/).
2.5. Cell migration/invasion assay
Migration and invasion assays were performed using transwell
chambers, as previously described [20]. In brief, the cells were re-
suspended in SFM (2 × 105 cells/mL) and loaded into transwell
chambers (upper chamber) in 100 μL. After 24 h, the cells were stained
by crystal violet and were counted (bottom chamber) under a micro-
scope. For the conditioned medium experiments, CL1-0 and H441 cells
were pretreated with the conditioned medium (CM) from IMPAD1-
overexpressing or IMPAD1-knockdowned CL1-5 cells for 48 h. Then,
the cells were trypsinized for the transwell cell migration and invasion
assays.
2.6. Animal studies
Animal experiments were conducted in accordance to the protocol
approved by the Animal Care and Use Committee of Kaohsiung Medical
University and Academia Sinica Institutional Animal Care. BALB/
cAnN.Cg-Foxn1nu/CrlNarl (immunodeficient mice) male mice were
used. For in vivo metastasis assay, CL1-5/shluc and CL1-5/shIMPAD1
cells were resuspended in PBS (1 × 106 cells/0.1 mL) and injected into
the tail vein of each group. For in vivo IMPAD1 overexpression model,
H441/Vector and H441/IMPAD1 cells were used 6-week-old nonobese,
diabetic, severe-combined immunodeficient (NOD-SCID) male mice. At
the end point, sections underwent H&E staining, and metastatic nodules
were then quantified under a microscope. For orthotopic metastasis
assay, the cells were resuspended in PBS and mixed with GFR-Matrigel
(BD Labware) (1:1); metastatic lung nodules were quantified using a
microscope.
2.7. AMP assay
The cells were plated at a density of 1 × 104 cells per well in 96-
well plates in complete medium and were incubated overnight at 37 °C
in 5% CO2. Following incubation, medium was replaced for each cell
line, which was incubated for 1 h. Moreover, 25 μL from each well was
transferred to a solid white plate. For AMP detection, the AMP-GloTM
assay (Promega, #V5011) was performed.
2.8. AMP replenishment
CL1-5/shluc and CL1-5/shIMPAD1 cells were plated at 3 × 105 in a
6-well plate in complete medium and were incubated overnight at 37 °C
in 5% CO2. On the next day, the cells were washed with complete
medium and treated with or without adenosine 5′-monophosphate
monohydrate (Sigma-Aldrich, #A2252, 38 nM) in complete medium.
2.9. ROS quantification
To evaluate cytoplasmic ROS, the cells were plated in a 6-well plate
(3 × 105) and were incubated overnight at 37 °C in 5% CO2.
Subsequently, the cells were incubated with 2′7′-dichlorodihydro-
fluorescein diacetate (DCFDA, 10 μM; Sigma-Aldrich, #D6883) for
20 min. Following the removal of DCFDA, the cells were resuspended in
PBS and analyzed through flow cytometry (Beckman Coulter Cytomics
FC500). To determine mitochondrial ROS, the cells were incubated in
MitoSOX (10 μM; Thermo Fisher Scientific, #M36008).
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2.10. Oxygen consumption rate and extracellular consumption rate
The OCR and ECAR were measured using an XFe-24 Analyzer
(Seahorse Bioscience). For the OCR assay, stable cell lines were treated
with or without 1 μM oligomycin, 0.5 μM carbonyl cyanide-p-tri-
fluoromethoxyphenylhydrazone (FCCP), 0.5 μM rotenone, and 0.5 μM
antimycin A (XF cell mito stress test kit, Seahorse Bioscience). For the
ECAR assay, stable cell lines were treated with or without 10 mM
glucose, 1 μM oligomycin, 0.5 μM rotenone, and 50 mM 2-deoxy-D-
glucose (2-DG) (XF glycolysis stress test kit, Seahorse Bioscience).
2.11. Complex I and complex III activity assay
Stable cell lines were plated in a 10-cm dish (5 × 106) in complete
medium at 37 °C for 24 h. On the next day, the cells were washed with
PBS, and mitochondria were then extracted using a mitochondria iso-
lation kit (#K228-50, BioVison). Complex I activity and Complex III
activity were determined using the Mitochondrial Complex I Activity
Colorimetric Assay Kit (#K968-100, BioVison) and Mitochondrial
Complex III Activity Assay Kit (#K520-100, BioVison). The results were
normalized to the protein concentration.
2.12. Statistical analysis
All statistical analyses were performed using SPSS software
(Statistical Package for the Social Sciences, version 19.0). Data are
presented as the mean ± SD, and data were analyzed using the two-
tailed Student t-test. Clinicopathological characteristics were compared
using the chi-square test. Correlations between parameters were ana-
lyzed using Spearman's correlation. P < 0.05 was considered sig-
nificant.
3. Results
3.1. Identification of IMPAD1 in the highly invasive CL1-5 cell line
To identify secretomic proteins associated with lung cancer inva-
sion, we analyzed proteins that were differentially expressed in condi-
tioned media between noninvasive CL1-0 lung cancer cells and their
relatively highly invasive counterpart CL1-5 cells [8] (Fig. 1A). We
identified that 15 proteins, putatively associated with lung cancer in-
vasion, were significantly enriched in the conditioned media of highly
invasive CL1-5 cells (Supplementary Table 1). Based on the Human
Protein Atlas (HPA) database (score> 2) and cDNA microarray data-
base (Kaplan–Meier Plotter and PrognoScan), we selected IMPAD1 for
further investigation (Supplementary Table 1). IMPAD1 was upregu-
lated in highly invasive CL1-5 cells, including in the conditioned
medium (CM) and cell extract (CE) (Fig. 1B and C). Moreover, RNA
levels of IMPAD1 were upregulated in CL1-5 and lung cancer tissues,
and IMPAD1 expression was associated with poor survival, as revealed
by a publicly available lung cancer microarray (GSE7670 and
GSE31210) and Kaplan–Meier survival analyses (Fig. 1D, F). We also
examined the protein levels of IMPAD1 in lung cancer patients by using
our lung cancer tissue array. Analysis of IMPAD1 expression was based
on the immunopositive staining of cytoplasmic IMPAD1 (Fig. 1G).
Using clarified expression criteria, we classified patients into an
IMPAD1-low group and an IMPAD1-high group (> 10%). The data
showed that high levels of IMPAD1 expression in lung cancer patients
was significantly associated with lymph node metastasis (P = 0.012)
(Supplementary Table 2). This result suggests that IMPAD1 is asso-
ciated with lung cancer progression.
3.2. Overexpression of IMPAD1 promotes lung cancer invasion and
metastasis
Our clinical findings suggest that IMPAD1 plays a role in lung
cancer progression. We investigated the effects of IMPAD1 perturbation
phenotype on invasion, migration, and proliferation abilities of lung
cancer cells. Endogenous IMPAD1 was upregulated in highly invasive
lung cancer cells CL1-5 and H1299 (Fig. 2A), and IMPAD1 knockdown
significantly reduced their migration/invasion abilities (Fig. 2B,
Supplementary Figs. 1A and C). Conversely, IMPAD1 overexpression
significantly increased migration/invasion in less invasive CL1-0 and
H441 lung cancer cell lines (Fig. 2C, Supplementary Figs. 1B and D).
Cell proliferation was not altered by knockdown or overexpression of
IMPAD1 in lung cancer cells (Supplementary Fig. 1E). We also ex-
amined the effect of the conditioned medium (CM) of CL1-5 cells with
high IMPAD1 expression on the migration and invasion potential of
CL1-0 and H441 cells. We pretreated CL1-0 and H441 cells with CM
from CL1-5 and CL1-5/shIMPAD1 cells and found that CM of CL1-5
promoted the migration/invasion abilities of CL1-0 and H441 cells,
which were suppressed by the CM of CL1-5/shIMPAD1 (Supplementary
Fig. 2A). Moreover, replenishment of IMPAD1 recombinant protein in
CM of CL1-5/shIMPAD1 cells restored the migration ability of CL1-0
and H441 cells (Supplementary Fig. 2B).
To further evaluate the effects of IMPAD1 on metastasis in vivo, we
intravenously (i.v.) injected IMPAD1-knockdown CL1-5 cells into the
lateral tail vein of mice. IMPAD1 knockdown resulted in reduced lung
metastases compared with controls (shluc) (Fig. 2D). We also quantified
the grade of lymph node invasion by scoring the levels of cytokeratin 18
(CK18) [21,22]. Compared with control (shluc), knockdown of IMPAD1
reduced CK18 expression in mouse lymph nodes (Fig. 2E). In a com-
parative experiment, IMPAD1 overexpression in H441 lung cancer cells
on metastasis was analyzed after i.v. injection and orthotopic (left lung)
implantation into mice. In the tail vein model, IMPAD1 overexpression
increased the number of metastatic lung foci (Fig. 2F). Moreover, si-
milar results were obtained for the orthotopic model, in which in-
creased numbers of metastatic lung foci were found in the right lung of
mice injected with the primary tumors formed in the left lung (Fig. 2G).
3.3. Upregulated IMPAD1 enhances Notch1-Mediated signaling and HEY1
expression
To identify the potential molecular mechanisms of IMPAD1, we
used gene expression RT2 profiler PCR arrays to examine control cells
(CL1-5/shluc) and IMPAD1-knockdown CL1-5 cells. Knockdown of
IMPAD1 resulted in the downregulation of the Notch1 pathway
(Fig. 3A, Supplementary Figs. 3A and B and Table 3). Furthermore, the
RNA level of Hes-Related Family BHLH Transcription Factor With
YRPW Motif 1 (HEY1), which is involved in the epithelial–mesench-
ymal transition (EMT) process [23], showed the highest down-
regulation in IMPAD1-knockdown cells (Fig. 3A). Western blotting and
real-time PCR also demonstrated that HEY1 expression was sig-
nificantly downregulated after IMPAD1 knockdown (Fig. 3B,
Supplementary Fig. 3C). Conversely, Western blotting confirmed that
HEY1 was upregulated in IMPAD1-overexpressing CL1-0 and H441 cells
compared with vector control cells (Fig. 3C). We therefore validated
that IMPAD1 promoted the migration and invasion abilities of lung
cancer cells through HEY1. As shown in Fig. 3D, migration and invasion
abilities were significantly inhibited in IMPAD1-overexpressing cells
through HEY1 suppression. These data suggest that IMPAD1 promotes
invasion through HEY1. Since HEY1 expression increases and accu-
mulation in the nucleus are regulated by Notch signaling [24,25], we
determined whether IMPAD1 activates Notch1. Indeed, the Notch sig-
naling reporter assay demonstrated that Notch activity was significantly
upregulated after IMPAD1 overexpression (Supplementary Fig. 3D). In
IMPAD1-overexpressing cells, migration and invasion abilities were
significantly inhibited through the suppression of Notch1 by using
shRNA or a γ-secretase inhibitor (DAPT) (Fig. 3E and F and
Supplementary Figs. 3E and F). We next investigated whether IMPAD1
expression is correlated with HEY1 expression in lung cancer patients
by immunohistochemistry (IHC). IHC staining for IMPAD1 and HEY1
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showed that IMPAD1 expression was positively correlated with HEY1
expression in the lung cancer tissues (Spearman nonparametric corre-
lation test; correlation coefficient = 0.262; P= 0.011; n = 77) (Fig. 3G
and H). Similar results were also observed in publicly available lung
cancer microarray datasets (GSE3141) (Supplementary Fig. 3G).
3.4. IMPAD1 modulates migration through the AMP-Dependent activation
of AMPK
AMPK is a sensor of energy status of cells and it can sense the
change ratio of AMP [26]. IMPAD1 is an enzyme responsible for the
conversion of PAP into AMP. We hypothesized that upregulated
IMPAD1 might increase AMP levels and activate the AMPK pathway. As
expected, IMPAD1 overexpression increased AMP levels, whereas
knockdown of IMPAD1 significantly reduced AMP levels (Fig. 4A and
B). IMPAD1 overexpression increased the expression of pAMPK in CL1-
0 and H441 cells (Fig. 4C). Conversely, knockdown of IMPAD1 in CL1-5
and H1299 cells significantly reduced the expression of pAMPK
(Fig. 4D). We further investigated whether IMPAD1 promotes migration
and invasion through the AMPK pathway. Indeed, treatment with BML-
275 (AMPK inhibitor) significantly inhibited migration and invasion
abilities in IMPAD1-overexpressing cells (Supplementary Fig. 4A).
We next studied whether IMPAD1 mediates HEY1 expression
through the AMPK pathway. IMPAD1 overexpression increased the
expression of Notch1 and HEY1, which was abolished by the AMPK
inhibitor BML-275 (Fig. 4E and Supplementary Fig. 4B). Conversely,
treatment with an AMPK activator led to Notch1 and HEY1 upregula-
tion in IMPAD1-knockdown cells (Fig. 4F). Moreover, AMP replenish-
ment restored migration ability and expression of pAMPK, Notch1 and
HEY1 in IMPAD1-knockdown cells (Fig. 4G and Supplementary Figs. 4C
and D). We next examined whether IMPAD1 expression was correlated
with pAMPK in the lung cancer tissue. IHC staining results showed that
the expression of IMPAD1 was positively correlated with pAMPK in
lung cancer tissues (Supplementary Figs. 4E and F). These data suggest
that IMPAD1 promotes lung cancer invasion and migration through the
AMPK-Notch1-HEY1 signaling pathway.
3.5. IMPAD1 modulates AMPK-HEY1 signaling through AMP-Dependent
activation of ADORA1 in lung cancer cells
In our study, IMPAD1 expression increased AMP levels in IMPAD1-
overexpressing cells (Fig. 4A). Since AMP can activate adenosine A1
receptor (ADORA1) and its expression is related to cancer progression
[27,28], we explored whether IMAPD1 regulates ADORA1 expression
in lung cancer cells. IMPAD1 overexpression caused ADORA1 upregu-
lation in CL1-0 and H441 lung cancer cells, whereas ADORA1 was
significantly reduced in IMPAD1-knockdown cells (Fig. 5A and B). We
further examined whether IMPAD1 mediates HEY1 expression through
ADORA1 in IMPAD1-overexpressing cells. Treatment with PD116,948
(an ADORA1 antagonist) reduced the expression of pAMPK and HEY1
in IMPAD1-overexpressing cells (Fig. 5C). Moreover, treatment with
L690,330 (a potent inhibitor of inositol monophosphatase) markedly
Fig. 1. Identification of IMPAD1 as a Potential Target for Lung Cancer Progression. (A) Schematic of secretomic protein screening in the conditioned medium of CL1-
0 and CL1-5 cells using a proteomic dataset. (B–C), Western blot analysis of IMPAD1 protein levels secreted into conditioned media (CM) (B) and cell extract (CE) (C)
from CL1-5 and CL1-0 cells. GLA, CALR, and β-actin were used as loading controls for CM and CE, respectively. (D) Relative IMPAD1 (218516_s_at) mRNA levels in
CL1-0 and CL1-5 lung cancer cells (NCBI/GEO/GSE7670). (E) Relative IMPAD1 (218516_s_at and 222655_s_at) mRNA levels in lung adenocarcinoma tissues (NCBI/
GEO/GSE31210). N = normal tissues, T = tumor tissues, and n = number of specimens. Data are presented as the mean ± SD; *P < 0.05. ns, not significant. (F)
The Kaplan–Meier overall survival curve constructed using publicly available lung cancer microarray datasets and stratified according to IMPAD1 expression. (G)
Representative images of IMPAD1 expression in lung adenocarcinoma tissues.
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reduced pAMPK and HEY1 expression in IMPAD1-overexpressing cells,
which is similar to the effect of PD116,948 (Fig. 5D). Furthermore,
Kaplan–Meier survival analyses revealed that ADORA1 expression was
associated with poor survival in lung cancer patients (Supplementary
Fig. 5). Taken together, our results suggest that IMPAD1 overexpression
provided AMP for activating ADORA1-AMPK signaling and increased
HEY1 expression, leading to lung cancer metastasis.
3.6. IMPAD1 inhibits electron transport in lung cancer cells, resulting in
decreased ROS production
AMPK can control mitochondria oxidative capacity and promote
Fig. 2. IMPAD1 enhances invasion/migration and metastasis in cell and animal models. (A) Western blot analysis of endogenous IMPAD1 in lung cancer cell
lines. Bottom, invasive abilities of lung cancer lines. (B) IMPAD1 knockdown and the invasion/migration abilities of CL1-5 and H1299 lung cancer cells. Top, Western
blot analysis of IMPAD1 after lentiviral-mediated RNAi. Bottom, migration (open) and invasion (filled) abilities of CL1-5 cells infected with shIMPAD1 or shluc
shRNA. Data are presented as the mean ± SD; **P < 0.01. (C) Effect of IMPAD1 overexpression on migration/invasion potential of CL1-0 and H441 lung cancer
cells. Top, Western blot analysis of IMPAD1 expression after IMPAD1 overexpression versus vector control treatment. Bottom, CL1-0 and H441 migration and
invasion abilities after IMPAD1 overexpression. Data are presented as the mean ± SD, and significance is determined using Student's t-test. **P < 0.01. (D) Top,
representative image of H&E-stained lung tissues from mice intravenously injected with CL1-5-shluc or CL1-5-shIMPAD1 (n = 9). Bottom, quantification of me-
tastatic lung nodules in individual mice 4 weeks after the tail vein was injected with CL1-5 cells after mice were infected with shluc or IMPAD1 shRNA1. Data are
presented as the mean ± SD, and the significance was determined using Student's t-test. **P < 0.01. (E) Representative images of CK18 expression in the lymph
nodes of shluc control mice and IMPAD1-knockdown mice. Data are presented as the mean ± SD, and the significance was determined using Student's t-test.
**P < 0.01. (F) Tail vein model, IMPAD1 overexpression and metastasis in vivo in H441 cells. Left, representative image of H&E-stained lung tissues from mice
intravenously injected with H441-Vector or H441-IMPAD1 cells (n = 5). Right, quantification of metastatic lung nodules in individual mice 4 weeks after the tail
vein was injected with H441 cells after infection with Vector or IMPAD1. (G) Orthotopic model, IMPAD1 overexpression and metastasis in vivo in H441.
Representative image of H&E-stained lung tissues from orthotopic mice injected with H441-Vector or H441-IMPAD1 cells (n = 4). Arrows indicate the H441/Vector
or H441/IMPAD1 tumor that was established in the left lung. The arrowhead indicates metastasis nodules on the right lung.
Y.-F. Yang, et al. Cancer Letters 485 (2020) 27–37
31
glucose uptake [29]. We evaluated whether IMPAD1 mediates the
metabolic pathway in IMPAD1-overexpressing and -knockdown cells by
analyzing the oxygen consumption ratio (OCR) and extracellular acid-
ification rate (ECAR) using the Seahorse XFp Analyzer. IMPADI over-
expression significantly reduced the OCR in IMPAD1-overexpressing
CL1-0 cells, whereas the OCR was increased in IMPAD1-knockdown
cells (Fig. 6A and B and Supplementary Fig. 6A). However, IMPAD1
expression did not affect ECAR in lung cancer cells (Supplementary
Figs. 6B–D). Mitochondria is not only responsible for ATP production
but also represents a source of cellular ROS [14]. To confirm the effect
of IMPAD1-inhibited OCR in mitochondria on ATP and ROS production,
we assessed ATP levels and ROS levels in IMPAD1-overexpressing cells.
As shown in Fig. 6C and D, IMPAD1 overexpression significantly re-
duced ROS levels and IMPAD1 knockdown significantly increased ROS
levels, whereas IMPAD1 expression did not affect ATP levels in lung
cancer cells (Supplementary Fig. 6E).
We next determined whether ROS accumulation correlates with the
migration and invasion abilities of lung cancer cells. H2O2 treatment
significantly inhibited migration/invasion abilities and reduced the
expression of pAMPK and HEY1 in IMPAD1-overexpressing cells
(Fig. 6E). Conversely, treatment with N-acetyl-L-cysteine (NAC) (a free
radical scavenger) restored the expression of pAMPK and HEY1 and
migration ability in IMPAD1-knockdown cells (Fig. 6F and
Supplementary Fig. 6F).
3.7. IMPAD1 inhibits ROS production through the regulation of
Mitochondrial Complex I
To determine whether mitochondrial ROS production was increased
in IMPAD1-knockdown cells, we analyzed ROS levels by using
MitoSOXRed. Results showed that mitochondrial ROS was increased in
IMPAD1-knockdown cells, whereas IMPDA1 overexpression reduced
mitochondrial ROS (Fig. 7A and B). In mitochondria, Complex I and
Complex III are ROS-producing systems [30]. To further examine their
effect, we measured Complex I and Complex III activity in mitochondria
and isolated them from IMPAD1-knockdown cells. Complex I activity
was higher in IMPAD1-knockdown cells but reduced in IMPAD1-over-
expressing cells (Fig. 7C and D), whereas the expression levels of
IMPAD1 had no effect on Complex III activity (Supplementary Figs. 7A
and B). We therefore determined whether Complex I mediates the ex-
pression of phosphorylated AMPK and HEY1. Indeed, treatment with
rotentone, a Complex I inhibitor, increased the expression of pAMPK
and HEY1 in IMPAD1-knockdown cells (Fig. 7E and Supplementary
Fig. 7C). These data suggest that upregulated IMPAD1 enhances inva-
sion by inhibiting Complex I activity, leading to reduced ROS produc-
tion (Fig. 7F).
4. Discussion
The data presented here add to a growing body of literature in-
dicating that metabolism in cancer cells contributes to the malignant
phenotype, and is critical to signal transduction, tumorigenesis, and
Fig. 3. IMPAD1 promotes invasion/migration through HEY1. (A) RNA levels of candidate genes relative to the shluc shRNA control. (B) Expression of IMPAD1
and HEY1 in CL1-5 and H1299 cells following IMPAD1 knockdown in comparison with the shluc shRNA control or IMPAD1 shRNA. (C) Western blot analysis of
IMPAD1 and HEY1 in CL1-0/IMPAD1 and H441/IMPAD1 cells. (D) Expression of HEY1 in CL1-0 cells overexpressing IMPAD1 in comparison with the vector control.
Top, Western blot analysis of IMPAD1 and HEY1 expression in CL1-0/IMPAD1 cells after HEY1 knockdown. Bottom, invasion and migration capabilities of CL1-0/
IMPAD1 cells after HEY1 knockdown. Data are presented as the mean ± SD. *P < 0.05; **P < 0.01. (E) Top, Western blot analysis of IMPAD1, Notch1 and HEY1
expression in CL1-0/IMPAD1 cells after Notch1 knockdown. Bottom, invasion and migration capabilities of CL1-0/IMPAD1 cells after Notch1 knockdown. Data are
presented as the mean ± SD. *P < 0.05; **P < 0.01. (F) Top, expression of IMPAD1, Notch1, and HEY1 in CL1-0/IMPAD1 cells after treatment with the γ-
secretase inhibitor DAPT (10 μM). Bottom, invasion and migration capabilities of CL1-0/IMPAD1 cells after treatment with the γ-secretase inhibitor. Data are
presented as the mean ± SD. *P < 0.05; **P < 0.01. (G) Representative IMPAD1 and HEY1 immunohistochemistry staining in a serial section of lung cancer
tissue array. (H) Analysis correlation of IMPAD1 and HEY1 expression in lung cancer tissues. Data are presented as the mean ± SD. *P < 0.05. NICD= Cleaved
Notch1.
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metastasis 30, 31. IMPAD1 was identified from the highly invasive CL1-5
compared with the relatively non-invasive counterpart, CL1-0 [8]. We
speculated the expression of IMPAD1 was correlated to invasion ability.
Indeed, IMPAD1 was highly expressed in the more invasive CL1-5 and
H1299 cells, but with low expression in the less invasive CL1-0 and
H441 cells. IMPAD1 overexpression promoted the migration and in-
vasion abilities in CL1-0 and H441 cells. Furthermore, IMPAD1 re-
plenishment in the conditioned medium of CL1-5/shIMPAD1 increased
the migration ability in CL1-0 and H441 cells. Together, these data
suggest that intracellular and extracellular IMPAD1 may play an im-
portant role in lung cancer migration and invasion abilities. Specifi-
cally, this study indicates for the first time that the secretomic protein
IMPAD1 is involved in lung cancer metastasis, both in patients’ clinical
data showing a significant association with lymph node metastasis, and
in vivo with a de novo pathway indicating that IMPAD1 mediated me-
tastasis through inhibition of mitochondrial Complex I activity to
Fig. 4. IMPAD1 drives AMPK activation in lung cancer cells. (A) Changes in total AMP levels in the conditioned medium of CL1-0/IMPAD1 and H441/IMPAD1
cells. (B) Total AMP levels in the conditioned medium of CL1-5 and H1299 cells after IMPAD1 knockdown. (C) Expression of pAMPK in CL1-0 and H441 cells
overexpressing IMPAD1 compared with the vector control. (D) Western blot analysis of pAMPK expression in CL1-5 and H1299 cells after infection with shluc or
IMPAD1 shRNA. (E) CL1-0/IMPAD1 cells were treated with DMSO or 10 μM BML-275 (as AMPK kinase inhibitor) for 24 h and analyzed through Western blotting. (F)
CL1-5/shIMPAD1 cells were treated with DMSO or 2 mM AICAR (as a AMPK activator) for 48 h and analyzed through Western blotting. (G) CL1-5/shIMPAD1 cells
were treated with vehicle or AMP (38 nM) for 192 h and analyzed through Western blotting.
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reduce ROS production, leading to AMPK phosphorylation, which in
turn induced Notch1-mediated upregulation of HEY1.
The IMPAD1 mutation is associated with chondrodysplasia and
abnormal joint development through impairment of its enzyme activity
[31], whilst loss of function in IMPAD1 leads to neonatal lethality in
mice [32]. Other than IMPAD1, 3′(2′), 5′-bisphosphate nucleotidase 1
(BPNT1) may have a similar function in converting PAP to AMP in the
cytoplasm [33]. IMPAD1 is a sulfotransferase that is normally located in
golgi and converts PAP into AMP in human fibroblasts [32]. In the
present study, we noted the upregulation of IMPAD1 and its mRNA
levels in the CM of highly invasive CL1-5 lung cancer cells, suggesting
that IMPAD1 is not only located in golgi but is also present in condi-
tioned medium with undefined functions. IMPAD1 overexpression in-
creased AMP levels in the CM of lung cancer cells, whereas decreased
AMP levels were found in IMPAD1-knockdown cells. We noted that
AMP replenishment restored the expression of pAMPK, Notch1, and
HEY1 and migration ability in IMPAD1-knockdown lung cancer cells.
Under energy stress conditions, AMPK promotes tumor cell survival
[13]. AMPK is a sensor of energy, and it can sense the change in AMP
levels, even at very low levels [26,34,35]. AMP regulates AMPK by
three complementary effects, including increased pAMPK by LKB1 [36],
inhibition of AMPK dephosphorylation by protein phosphatase-2C
alpha (PP2C alpha) [37], and allosteric activation [34]. AMPK activa-
tion also plays a critical role under energy stress conditions such as
anchorage-independent growth. In particular, LKB1 appears to play a
critical role under energy stress conditions such as anchorage-in-
dependent growth and solid tumor formation, promoting cell survival
by AMPK activation and redox regulation [13]. LKB1-deficient cells are
therefore resistant to oncogenic transformation and tumorigenesis
[13,38]. LKB1 homozygous deletions and mutation are rare in somatic
tumors, yet strikingly in NSCLC rates of 39% are reported, with up to
90% NSCLC showing loss of a single or both copies of the LKB1 locus
[39]. A key unanswered question is therefore how LKB1 deficient
NSCLC tumor cells can escape or bypass metabolic requirements during
energy stress conditions [13]. Activation of AMPK restores ATP levels
and promotes cell survival [13,40]. Overexpression of IMPAD1 may
therefore provide one such an alternate pathway to AMPK activation in
LKB1 deficient NSCLC (Fig. 7F). Although not the main focus of the
present study, neither overexpression nor knockdown of IMPAD1 in
lung cancer cells affected cell growth and ATP levels. Further work will
be directed towards IMPAD1 overexpression and knockdown in LKB1
knockout models.
In the present study, we found that IMPAD1 overexpression in-
creased pAMPK expression in lung cancer cells, whereas knockdown of
IMPAD1 reduced pAMPK expression in lung cancer cells, by modulating
AMP levels. Moreover, IMPAD1 expression increased AMP levels in the
CM of lung cancer cells. AMP is also an ADORA1 agonist; treatment
with an ADORA1 antagonist (PD116,948) significantly reduced the
expression of pAMPK in IMPAD1-overexpressing cells. Similar to our
results, Dada et al. also showed that the ADORA1 agonist 2-chloro-N6-
cyclopentyladenosine increased expression of pAMPK in alveolar epi-
thelial cells [41]. Although we cannot exclude other pathways in AMP
synthesis, this is the first study to demonstrate that IMPAD1 over-
expression induces the upregulation of pAMPK by AMP through
ADORA1.
Prior studies have indicated that Notch is involved in the regulation
of glycolytic and oxidative metabolism, promoting glucose uptake and
increasing OCR in T-cell acute lymphoblastic leukemia (T-ALL). Notch
also activates AMPK to inhibit anabolic metabolism [42]. Similarly, our
data showed that IMPAD1 overexpression upregulated the expression of
Notch1 and reduced OCR in lung cancer cells). Furthermore, treatment
with AMPK inhibitor BML-275 inhibited the expression of Notch1 and
HEY1 in IMPAD1-overexpressing cells, whereas treatment with either
the AMPK activator AICAR or with AMP restored Notch1 and HEY1
expression in IMPAD1-knockdown cells. Treatment with an IMPAD1
inhibitor (L690,330) reduced pAMPK expression in 24 h and HEY1
expression in 48 h in IMPAD1-overexpressing cells, whereas treatment
with NAC (a free radical scavenger) restored pAMPK expression in 4h
and HEY1 expression in 24h in IMPAD1-knockdown cells. This finding
suggests that AMPK modulates Notch1 and HEY1 expression in
IMPAD1-overexpressing cells.
AMPK can promote mitochondrial oxidative metabolism through
Fig. 5. IMPAD1-mediated ADORA1 acti-
vation is AMP-dependent in lung cancer
cell lines. (A) ADORA1 expression and
IMPAD1 expression were compared be-
tween CL1-0/IMPAD1 and H441/IMPAD1
cells and CL1-0/Vector and H441/Vector
cells. (B) Expression of ADORA1 was com-
pared between CL1-5 and H1299 cells with
IMPAD1 knockdown and the shluc control.
(C) CL1-0/IMPAD1 cells were treated with
PD116,848 (10 μM, a ADORA1 antagonist)
and assayed using Western blot with the
indicated antibodies. (D) IMPAD1-over-
expressing cells were treated with L690,330
(100 μM, as a IMPAD1 enzyme inhibitor)
for 24 h and 48 h and were assayed using
Western blotting with the indicated anti-
bodies.
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the modulation of Complex I activity [29,42]. The suppression of AMPK
in T-ALL has been shown to reduce Complex I activity and OCR levels,
leading to an increase in ROS levels. In T-ALL, AMPK is essential for
maintaining mitochondria capacity [42]. Elizabeth et al. showed that
treatment with H2O2 activated AMPK in C2C12 mouse myotubes [43].
In the present study, we showed that IMPAD1 overexpression inhibited
Complex I activity and reduced ROS levels, leading to the increased
expression of pAMPK in lung cancer lines. Treatment with NAC (a free
radical scavenger) or rotentone (Complex I inhibitor) restored the ex-
pression of pAMPK in IMPAD1-knockdown cells. In contrast, treatment
with H2O2 reduced pAMPK expression and inhibited migration/inva-
sion abilities in IMPAD1-overexpressing cells. In agreement with our
results, previous studies have shown that suppression of Complex I
activity enhanced cell migration and invasion in breast cancer cell lines
[44], and treatment with H2O2 reduced the expression of AMPK in a
cardiomyocyte ischemia model [45]. Our data demonstrated that
IMPAD1 inhibited mitochondrial Complex I activity, leading to de-
creased levels of ROS; thus increased pAMPK and HEY1 expression
promoted migration and invasion abilities in lung cancer cells.
Recently Gamma secretase inhibitors (GSI), a class of small-mole-
cule inhibitors that prevent the cleavage of γ‐secretase substrates in-
cluding the four Notch receptors and the five canonical transmembrane
Notch ligands [46], have been explored in the context of NSCLC with
the aim of sensitising tumors to chemotherapeutic agents such as pa-
clitaxel [47]. However, somatic mutations in Notch are rare in NSCLC
[48], perhaps accounting for the variable clinical efficacy of GSIs such
Fig. 6. Mitochondrial dysfunction in IMPAD1-overexpressing lung cancer cell lines. (A–B) Analysis of the oxygen consumption rate (OCR) in CL1-0/IMPAD1
cells (A) and CL1-5/shIMPAD1 cells (B). (C) Left, analysis of the ROS level by flow cytometry analysis of DCFDA in CL1-0/IMPAD1 and H441/IMPAD1 cells. Right,
quantification of ROS level. Data are presented as mean ± SD. **P < 0.01. (D) Left, analysis of the ROS level by flow cytometry analysis of DCFDA in CL1-5 and
H1299 cells with IMPAD1 knockdown. Right, quantification of ROS level. Data are presented as the mean ± SD. **P < 0.01. (E) IMPAD1-overexpressing cells were
treated with H2O2 (80 μM) and assayed for Western blotting with the indicated antibodies (top) or invasion and migration using transwell chambers (bottom). Data
are presented as the mean ± SD. *P < 0.05; **P < 0.01. (F) IMPAD1-knockdown cells were treated with NAC (10 mM) for 4 h and 24 h and assayed using Western
blotting with the indicated antibodies (left) or migration using transwell chambers (right). Data are presented as the mean ± SD. *P < 0.05; **P < 0.01.
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as AL101 [47,49]. Given that IMPAD1 is an upstream effector of
Notch1, overexpression of IMPAD1 may provide a more suitable bio-
marker for GSI efficacy in NSCLC, and may allow therapeutic stratifi-
cation of subsets of patients who are most likely to benefit. Further
therapeutic targets in the IMPAD1-pAMPK-Notch1-HEY1 pathway in-
clude AMPK agonists, with the use of Mitochondrial complex I in-
hibitors such as metformin and phenformin [50,51], and more recently
AMPK specific agonists such as D561-0775 in NSCLC showing promise
in preclinical studies [52]. However, lack of efficacy in translational
clinical studies of metformin with gefitinib, again points towards the
need for a suitable biomarker for patient stratification [53].
The data presented here identified IMPAD1 for the first time as a
clinically relevant metastasis-associated protein and prognostic marker
in lung cancer patients. Significantly, we discovered a novel IMPAD1-
pAMPK-Notch1-HEY1 pathway that promoted migration and invasion
of lung cancer cells. IMPAD1 overexpression inhibited Complex I ac-
tivity, reducing ROS production in lung cancer cell, promoting tumor
cell invasion. Lastly, IMPAD1 may be critical in tumor metabolic re-
programming of NSCLC, providing an alternate route to activation of
AMPK under energy stress conditions. Collectively our data suggests
that IMPAD1 is a propitious metabolic therapeutic target and a novel
biomarker in lung cancer metastasis that may allow stratification of
emerging therapies such as GSIs.
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